All News

ViewPoints: Dicerna, Alnylam make for strange bedfellows in RNAi

Ref: ViewPoints Desk

Tags: ViewPoints Dicerna Alnylam Clinical Research (R&D) Corporate Affairs Licensing ALN-AAT02 DCR-A1AT Nedosiran lumasiran

Tarveda Therapeutics Provides Update on Proposed Merger with Organovo

Ref: Business Wire

Tags: Press Release Organovo Tarveda Therapeutics Corporate Affairs Mergers & Acquisitions

KOL Views: How are COVID-19 treatment regimens evolving on the front lines

Ref: KOL Views Desk

Tags: KOL Views Gilead Regeneron Sanofi Lilly Amgen Vir Biotechnology Viral Infections FDA Clinical Research (R&D) Regulatory Affairs Remdesivir

Oramed Patent in Canada Allowed for Oral Delivery of Proteins

Ref: PR Newswire

Tags: Press Release Oramed Corporate Affairs

Novant Health Initiates Phase 2 COVID-19 Trial with CytoDyn’s Leronlimab

Ref: GlobeNewswire

Tags: Press Release CytoDyn COVID-19 Clinical Research (R&D)Leronlimab

Cantargia provides update on development projects CAN04 and CAN10

Ref: Cision

Tags: Press Release Cantargia Pancreatic Cancer Lung Cancer Clinical Research (R&D) Corporate Affairs CAN04 CAN10

Cantargia submits IND application for CAN04

Ref: Cision

Tags: Press Release Cantargia FDA Regulatory Affairs CAN04 Keytruda

Oral antiviral shows promising early results against COVID-19, says new study

Ref: Xinhua

Tags: NewsPoints COVID-19 Clinical Research (R&D)EIDD-2801

FDA Clears the Way for Ridgeback Biotherapeutics to begin Human Testing of a Promising Potential Treatment for COVID-19

Ref: PR Newswire

Tags: Press Release Ridgeback Biotherapeutics COVID-19 FDA Regulatory Affairs EIDD-2801

CDC removes unusual guidance to doctors about drug favored by Trump

Ref: Financial Post

Tags: NewsPoints COVID-19 CDC Medical Affairs chloroquine hydroxychloroquine